Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

NCT02123199 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2014-04-25

No results posted yet for this study

Summary

A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Indacaterol (Onbrez®) /QAB149

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-12-31

Countries

  • United Kingdom

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02123199 on ClinicalTrials.gov